MassDevice

RenovoRx reports first patient procedure with RenovoCath in post-marketing registry study

RenovoRx (Nasdaq: RNXT) this week said its RenovoCath drug-delivery device was used for the first time in its post-marketing registry study. The case was performed at the University of Vermont Cancer ...
Business Insider

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of ...